Error message

The page you requested does not exist. For your convenience, a search was performed using the query news events news 2017 10 30.

Page not found

You are here

Tue, August 22, 2017

A new study finds that more than half of women with early stage breast cancer consider an aggressive surgery to remove both breasts. The way women generally approach big decisions, combined with their values, affects which breast cancer treatment they think about, the study also found.

CBSSM members, Sarah Hawley and Reshma Jagsi, were authors on this study.

 

Panel Discussion: Ethical, Legal, and Social Implications of Genetics and Newborn Screening

Mon, September 25, 2017, 6:00pm
Location: 
Vandenberg Room, Michigan League

Join Joselin Linder, author of “The Family Gene”, and Jodyn Platt, assistant professor in the U-M Medical School in a panel discussion about the ethical, legal, and social implications of genetics and newborn screening. The conversation will be moderated by Kayte Spector-Bagdady, assistant professor in the U-M Medical School and chief of the research ethics service in the Center for Bioethics and Social Sciences in Medicine.

Tue, September 26, 2017

Dean Shumway, Rochelle Jones, Sarah Hawley, and Reshma Jagsi are co-authors of a study, published in the Annals of Surgical Oncology, which found that clinician attitudes and patient expectations are driving overtreatment of radiotherapy in older breast cancer patients.

Fri, September 15, 2017

A study on surgeon influence on double mastectomy co-authored by Sarah Hawley and Reshma Jagsi was recently highlighted in Time Health.  This study found that attending surgeons exerted a substantial amount of influence on the likelihood of receipt of contralateral prophylactic mastectomy after a breast cancer diagnosis. Steven Katz was first author of this study.

Mon, October 02, 2017

Sarah Hawley, Brian Zikmund-Fisher, and Reshma Jagsi are co-authors of a recent study published in Medical Decision Making, which was highlighted in MHealth Lab. Their study found that talking to clinicians is the best way for breast cancer patients to understand their recurrence risk. They also found that clinician discussions about recurrence risk should address uncertainty and the relevance of family and personal history. Kamaria Lee is first author of the article.

Wed, October 11, 2017

In an editorial in Nature Human Behaviour, Brian Zikmund-Fisher discusses the findings of a recent study about the unintended consequences of argument dilution in direct-to-consumer drug advertising. In a series of experiments, study authors, Niro Sivanathan and Hemant Kakker found that long lists of serious and minor side effects found in drug advertisements actually "dilute" consumers' judgments of the overall risk from side effects.

Thu, October 26, 2017

In a new analysis in Health Affairs, CBSSM's Jeffrey Kullgren and fellow researchers found that while the "Choosing Wisely" campaign to reduce overtesting and overtreatment is off to a strong start, more work is still needed to cut back on low-value care.

CBSSM Seminar: Jan Van den Bulck, PhD

Tue, November 28, 2017, 3:00pm
Location: 
NCRC, Building 16, Room 266C

Jan Van den Bulck, PhD
Professor, Communication Studies

Topic:
"Are the media (re-)defining how we interact with each other and with the world?

We know everything there is to know about people we have never even met. Through social media, we follow their every move. We even know their pets. Our media use interferes with healthy sleep, family meals, or even our work. Our children need levels of self-control to manage distractions that threaten their schoolwork. Or do they?"

Tue, November 28, 2017

In a study published in JAMA Internal Medicine, Jeff Kullgren and co-authors found that few individuals enrolled in High-Deductible Health Plans (HDHPs) in the United States are engaging in consumer behaviors.

Bioethics Grand Rounds -Nicholson Price, Asst Professor of Law

Wed, September 27, 2017, 12:00pm
Location: 
UH Ford Auditorium

Nicholson Price, Asst Professor of Law - "Black-Box Medicine"

Big data has been coming to health care for several years, and artificial intelligence is approaching even more rapidly.  What happens when these two phenomena meet in the context of clinical care?  How should clinicians deal with algorithms (whether embedded in EHRs or found on patients’ smartphones) that can predict outcomes, suggest diagnoses, and even recommend courses of treatment—all without explaining how they reach their conclusions?  This talk will describe the burgeoning field of black-box medicine, consider how the FDA can and should regulate this technology, and address liability and implementation concerns for clinicians today and in the near future.

 

Pages